The C2C12 muscle atrophy model is the standard in vitro system for studying muscle wasting — cancer cachexia, aging, disuse, or glucocorticoid exposure — where fibers shrink and strength slips. This application note walks the wasting pathway the way you’d actually study it in C2C12 myotubes, with the exact reagent for each step and the atrophy markers worth measuring. Browse the full ELISA kit, antibody, and cell line ranges for any target not shown. Jump to what you need.
The C2C12 muscle atrophy model
Start in C2C12 myotubes. C2C12 is a subclone of mouse skeletal myoblasts and the workhorse of muscle-wasting research. In high serum the cells proliferate as mononucleated myoblasts; switch them to low-serum differentiation medium and they exit the cell cycle, fuse, and form multinucleated, contractile myotubes that express myosin heavy chain and other sarcomeric proteins.
Atrophy is then induced in the mature myotubes — most commonly with the synthetic glucocorticoid dexamethasone, with TNF-α, or by serum/amino-acid starvation — each of which activates the atrogene program within hours to days. Typical readouts are myotube diameter, myosin heavy-chain content, and induction of Atrogin-1 and MuRF1. Because these same triggers reproduce the in vivo phenotype, C2C12 remains the standard first-pass system for mechanism and drug-screening work.
Growth signals: IGF-1 / AKT / mTOR versus myostatin
Atrophy often begins when growth signals fall. Muscle size is set by a tug-of-war between two hormonal inputs. IGF-1 activates PI3K and AKT, and active AKT does two jobs at once: it switches on mTOR complex 1 (mTORC1, built around the RAPTOR scaffold) to drive protein synthesis through S6K1 and 4E-BP1, and it phosphorylates the FoxO transcription factors to hold them out of the nucleus and keep the atrophy program silent. mTOR complex 2 (mTORC2, defined by RICTOR) closes the loop by phosphorylating AKT at Ser473.
Pulling the other way, myostatin (GDF8) and the activins bind the ActRIIB receptor and signal through Smad2/3 to restrain growth. Because a drop in anabolic tone — not only a rise in breakdown — can tip a fiber into net loss, profiling both arms is what separates true wasting from a simple synthesis defect.
FoxO3: the master switch from growth to wasting
FoxO3 flips muscle from growth to wasting. The FoxO transcription factors are where the atrophy signal converges. While AKT is active, FoxO1 and FoxO3 sit phosphorylated in the cytoplasm; when AKT signaling drops — during fasting, glucocorticoid exposure, or disuse — they are dephosphorylated, move into the nucleus, and transactivate the “atrogenes.”
FoxO3 is potent enough on its own to induce both muscle-specific ubiquitin ligases (below) and to switch on the autophagy machinery, so it commands both major degradation systems in parallel. That dual role makes nuclear or total FoxO3 one of the earliest and most informative markers of the growth-to-wasting transition.
Atrogin-1 and MuRF1: the benchmark muscle atrophy markers
If you track just two markers, track these. The ubiquitin–proteasome system does most of the regulated protein breakdown in atrophying muscle, and two muscle-specific E3 ubiquitin ligases are its signature effectors. Atrogin-1/MAFbx (FBXO32), part of an SCF complex, goes after the growth and differentiation machinery — targeting MyoD and the translation initiation factor eIF3-f to shut protein production down. MuRF1 (TRIM63), a RING-finger ligase, ubiquitinates thick-filament sarcomeric proteins such as myosin heavy chain, physically dismantling the contractile apparatus.
Both are transcriptionally induced early — often before any mass is measurably lost — and across essentially every model of wasting, from denervation to fasting to cancer cachexia. Their mRNA and protein levels rise together and scale with the severity of the response, which is exactly why they are the field’s benchmark atrophy markers.
Autophagy in muscle atrophy: the LC3-I → LC3-II shift
Watch the LC3-I → LC3-II shift. Alongside the proteasome, the autophagy–lysosome system clears bulk cytoplasm, protein aggregates, and damaged organelles including mitochondria — and it, too, is under FoxO3 control, through targets such as LC3 and Bnip3. The diagnostic readout is the conversion of soluble LC3-I to lipidated LC3-II, which inserts into autophagosome membranes and runs as a distinct, faster-migrating band on a western blot.
Both too little and too much autophagic flux damage muscle, so the LC3-II signal is quantified — ideally with lysosomal inhibitors to capture true flux rather than a static snapshot — when interpreting an atrophy phenotype.
Cancer cachexia signals: TNF-α and IL-6
In cachexia, the trigger comes from outside the muscle. In cancer and systemic inflammation, the wasting signal is delivered by circulating cytokines rather than generated inside the fiber. TNF-α acts through the IKKβ/NF-κB axis, and IL-6 signals via gp130/JAK/STAT3; both converge on atrogene induction and suppression of myogenic differentiation, and elevated serum IL-6 in particular tracks with weight loss in patients.
Measuring these cytokines in serum, plasma, or myotube-conditioned medium ties a whole-animal or clinical phenotype back to the intracellular pathways above, and gives you pharmacodynamic markers when testing anti-cachexia interventions.
Proving causality with Fbxo32 and Trim63 siRNA knockdown
Marker up? Now prove it matters. Showing that Atrogin-1 or MuRF1 rises during atrophy is correlation; showing that removing it protects the fiber is causation. Silencing either ligase blunts myotube shrinkage — and for MuRF1, spares myosin heavy chain — which is why RNAi knockdown is the standard next step once a marker moves.
Pre-designed siRNA sets against Fbxo32 and Trim63 (human, mouse, and rat) supply multiple validated duplexes plus positive and negative controls per target, ready to transfect into differentiated C2C12 myotubes for loss-of-function and epistasis experiments.
All reagents at a glance
| Step | Reagent | Type | Species |
|---|---|---|---|
| Model | C2C12 Cell Line | Cell line | Mouse |
| Growth | IGF-1 ELISA | ELISA | Mouse |
| Growth | Myostatin / GDF8 ELISA | ELISA | Mouse (H/R avail.) |
| Growth | RPTOR (mTORC1) ELISA | ELISA | Human |
| Growth | RICTOR (mTORC2) ELISA | ELISA | Human |
| Switch | FOXO3 Antibody | Antibody | — |
| Switch | FOXO3 ELISA | ELISA | Mouse (H/R avail.) |
| Effector | Atrogin-1 / FBXO32 ELISA | ELISA | Mouse (H/R avail.) |
| Effector | Recombinant FBXO32 Protein | Protein | Human |
| Effector | MuRF1 / TRIM63 ELISA | ELISA | Mouse (H/R avail.) |
| Effector | Anti-MuRF1 (TRIM63) Antibody | Antibody | Human |
| Autophagy | Anti-LC3B Antibody | Antibody | — |
| Cachexia | TNF-α ELISA | ELISA | Mouse |
| Cachexia | IL-6 ELISA | ELISA | Mouse |
| Knockdown | Fbxo32 Pre-designed siRNA | siRNA | Mouse (H/R avail.) |
| Knockdown | Trim63 Pre-designed siRNA | siRNA | Mouse (H/R avail.) |
Browse ELISA Kits Request Bulk Pricing
Frequently asked questions
What is the best cell model for studying muscle atrophy?
C2C12 mouse myotubes are the standard in vitro muscle atrophy model. Myoblasts are differentiated into multinucleated, contractile myotubes, then atrophy is induced pharmacologically or by starvation, giving a reproducible system for mechanism and drug-screening studies.
How do you induce atrophy in C2C12 myotubes?
The most common triggers are the synthetic glucocorticoid dexamethasone, the inflammatory cytokine TNF-α, and serum or amino-acid starvation. Each activates the atrogene program within hours to days, reducing myotube diameter and inducing Atrogin-1 and MuRF1.
What are the main markers of muscle atrophy?
The two benchmark markers are the muscle-specific E3 ubiquitin ligases Atrogin-1/MAFbx (FBXO32) and MuRF1 (TRIM63), which are induced early across essentially every wasting model. FoxO3 activation and the LC3-I→LC3-II autophagy shift are complementary readouts.
What is the difference between Atrogin-1 and MuRF1?
Both are FoxO3-driven E3 ligases, but they target different substrates. Atrogin-1/FBXO32 targets growth and differentiation factors such as MyoD and eIF3-f to suppress protein synthesis, whereas MuRF1/TRIM63 ubiquitinates sarcomeric proteins such as myosin heavy chain to dismantle the contractile apparatus.
How is autophagy measured in muscle atrophy?
By the conversion of soluble LC3-I to lipidated LC3-II, detected as a faster-migrating band on a western blot with an anti-LC3B antibody. Adding a lysosomal inhibitor lets you measure true autophagic flux rather than a static snapshot.
How is cancer cachexia modeled in vitro?
By treating C2C12 myotubes with cachexia-associated cytokines, chiefly TNF-α (IKKβ/NF-κB) and IL-6 (gp130/JAK/STAT3), or with tumor-cell–conditioned medium. The cytokines can then be quantified in the conditioned medium as pharmacodynamic markers.
Further reading
- Sartori R, Romanello V, Sandri M. Mechanisms of muscle atrophy and hypertrophy. Nat Commun. 2021;12:330. PubMed
- Bodine SC, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704. PubMed
- Gomes MD, et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. PNAS. 2001;98:14440. PubMed
- Sandri M, et al. Foxo transcription factors induce atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117:399. PubMed
- Stitt TN, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 2004;14:395. PubMed
- McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature. 1997;387:83. PubMed
- Clarke BA, et al. The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 2007;6:376. PubMed
- Mammucari C, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007;6:458. PubMed
- Cai D, et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell. 2004;119:285. PubMed
- Bonetto A, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6. Am J Physiol Endocrinol Metab. 2012;303:E410. PubMed
